Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorZhu, Zhen-
Autor(es): dc.creatorLu, Zhaohui-
Autor(es): dc.creatorXu, Tianmin-
Autor(es): dc.creatorChen, Cong-
Autor(es): dc.creatorYang, Gang-
Autor(es): dc.creatorZha, Tao-
Autor(es): dc.creatorLu, Jianchun-
Autor(es): dc.creatorXue, Yuan-
Data de aceite: dc.date.accessioned2026-02-09T12:05:01Z-
Data de disponibilização: dc.date.available2026-02-09T12:05:01Z-
Data de envio: dc.date.issued2020-07-02-
Data de envio: dc.date.issued2020-07-02-
Data de envio: dc.date.issued2020-07-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/41665-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0163445320301882-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1153941-
Descrição: dc.descriptionLopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases) and arbidol group (16 cases). Lopinavir/ritonavir group received 400 mg/100mg of Lopinavir/ritonavir, twice a day for a week, while the arbidol group was given 0.2 g arbidol, three times a day. Data from these patients were retrospectively analyzed. The cycle threshold values of open reading frame 1ab and nucleocapsid genes by RT-PCR assay were monitored during antiviral therapy. None of the patients developed severe pneumonia or ARDS. There was no difference in fever duration between the two groups (P=0.61). On day 14 after the admission, no viral load was detected in arbidol group, but the viral load was found in 15(44.1%) patients treated with lopinavir/ritonavir. Patients in the arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group (P<0.01). Moreover, no apparent side effects were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceJournal of Infection-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-
Palavras-chave: dc.subjectCt value-
Palavras-chave: dc.subjectAntiviral therapy-
Palavras-chave: dc.subjectPneumonia-
Título: dc.titleArbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.